|
End-of-day quote
Taiwan S.E.
01/10/2026
|
5-day change | 1st Jan Change | ||
| 49.00 TWD | +0.10% |
|
+1.98% | -17.37% |
| Market Cap | 5.89B 184M 164M 153M 140M 263M 17.75B 266M 1.85B 717M 9.04B 692M 677M 29.04B | P/E 2024 |
52.9x | P/E 2025 | 16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 7.01B 219M 195M 182M 166M 312M 21.11B 317M 2.2B 853M 10.75B 823M 805M 34.54B | EV / Sales 2024 |
2x | EV / Sales 2025 | 1.7x |
| Free-Float |
78.86% | Yield 2024 |
4.36% | Yield 2025 | 5.06% |
| 1 day | +0.10% | ||
| 1 week | +1.98% | ||
| Current month | +0.10% | ||
| 1 month | +0.51% | ||
| 3 months | -8.75% | ||
| 6 months | -12.50% | ||
| Current year | -17.37% |
| 1 week | 47.45 |  | 49.3 |
| 1 month | 45 | | 49.6 |
| Current year | 45 | | 62.5 |
| 1 year | 45 | | 68.6 |
| 3 years | 45 | | 121 |
| 5 years | 44.2 | | 121 |
| 10 years | 29.75 | | 121 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
CEO | Chief Executive Officer | - | 31/12/1995 |
Yue Chen Lo
DFI | Director of Finance/CFO | - | 13/04/2003 |
Chin Yuan Lin
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
CHM | Chairman | - | 31/12/1995 |
Che Jen Chuang
BRD | Director/Board Member | - | 17/06/2012 |
Hung Min Hsieh
BRD | Director/Board Member | - | 27/08/2006 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.10% | +1.98% | -26.20% | -44.13% | 184M | |
| -0.62% | -2.71% | +39.30% | +114.07% | 1,025B | |
| -2.30% | -4.44% | +39.03% | +66.07% | 623B | |
| -0.63% | -1.96% | +6.36% | +74.38% | 459B | |
| -1.03% | -2.82% | +59.56% | +39.69% | 355B | |
| +0.10% | -3.33% | +22.51% | +40.42% | 336B | |
| +0.39% | -1.15% | +13.84% | +26.83% | 270B | |
| +0.12% | -4.06% | -3.31% | +9.97% | 247B | |
| -3.38% | +0.30% | +36.44% | +51.54% | 220B | |
| -1.04% | -1.46% | +32.70% | +96.82% | 183B | |
| Average | -0.85% | -1.63% | +22.02% | +47.57% | 371.84B | |
| Weighted average by Cap. | -0.96% | -2.11% | +30.43% | +69.57% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 4.73B 148M 131M 123M 112M 211M 14.25B 214M 1.49B 576M 7.26B 556M 544M 23.31B | 4.85B 152M 135M 126M 115M 216M 14.62B 219M 1.53B 590M 7.44B 570M 558M 23.91B |
| Net income | 157M 4.92M 4.37M 4.09M 3.72M 7.01M 474M 7.11M 49.45M 19.14M 241M 18.48M 18.08M 775M | 441M 13.8M 12.26M 11.46M 10.45M 19.67M 1.33B 19.94M 139M 53.69M 677M 51.82M 50.7M 2.17B |
| Net Debt | 1.2B 37.42M 33.24M 31.08M 28.33M 53.33M 3.6B 54.06M 376M 146M 1.83B 141M 137M 5.89B | 1.12B 34.9M 31M 28.99M 26.42M 49.74M 3.36B 50.42M 351M 136M 1.71B 131M 128M 5.5B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/10/26 | NT$49.00 | +0.10% | 444,421 |
| 30/09/26 | NT$48.95 | +2.62% | 1,019,870 |
| 29/09/26 | NT$47.70 | -0.73% | 873,374 |
| 24/09/26 | NT$48.05 | -1.23% | 644,992 |
| 23/09/26 | NT$48.65 | +0.93% | 893,123 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4746 Stock
Select your edition
All financial news and data tailored to specific country editions
